Variables to Consider and Possible Links to Failures in Clinical Trials
Empirical risk factors, complexity indicators, and early warning patterns observed across 602,514 studies.
Key Variables & Data Dimensions Gathered
To evaluate termination risk factors comprehensively, this project brings together multidimensional indicators from 602,514 registered clinical studies. The dimensions below describe what each study contributes to the analysis and why it matters when looking for early warning signs.
NoteThe Dataset at a Glance
- The analysis covers all studies, including the 34,295 studies that were marked TERMINATED out of the complete AACT dataset.
- The TERMINATED studies represent 5.7% of all studies and 9.4% of studies with a resolved outcome.
- The dataset includes 459,840 interventional studies alongside 140,623 observational studies.
- 30,742 terminated studies include a documented reason for stopping, giving the analysis a direct view of reported causes.
Variables Collected Across Clinical Dimensions
| Domain | Key Variables Gathered | Description & Analytical Value |
|---|---|---|
| Study Identification & Status | Study identifier, overall study status, termination indicator, and reported reason for stopping | Tracks each trial across 14 status categories and captures the documented rationale for more than 30,000 terminated studies. |
| Recruitment & Scale | Planned enrollment and enrollment type | Quantifies expected participant cohorts and distinguishes planned targets from actual participant accumulation. |
| Development Phase | Phase I, II, III, IV, mixed, or not applicable | Shows how termination patterns change from early safety testing to large-scale confirmatory trials. |
| Sponsorship & Funding | Lead sponsor type, lead organization, and sponsor count | Groups sponsors into industry, academic or hospital, NIH, and federal categories to examine funding context. |
| Study Design & Complexity | Randomized design, placebo use, number of treatment arms, and number of sites | Captures protocol structure, control groups, and the operational reach of each study. |
| Timeline & Duration | Start year, start date, completion date, and study duration | Follows trial activity across 36 years, from 1990 to 2026, and measures how long studies remain active before resolution. |
These measures are descriptive signals rather than guarantees of failure. Together, they help researchers compare study designs, identify patterns associated with termination, and focus prevention efforts where they may have the greatest value.
1. Study Status & The Scope of Termination
Across the full registry of 602,514 studies, 34,295 are explicitly recorded as TERMINATED. The interactive chart below, similar to the one on the Home page, contrasts total registered studies against those marked terminated across all primary status categories. Use the buttons to toggle between linear and logarithmic scale to inspect low-frequency status categories, or hover over bars for exact counts and registry shares.
NoteUnderstanding Closed vs Active Statuses
While the baseline termination rate across all registered records is 5.7%, among closed, definitive trials (completed + terminated: 363,391 studies), the realized termination rate is 9.4%—approaching 1 in every 10 trials.
2. Trial Size Over Time: Interactive Panel of Histograms
Trial enrollment is one of the most critical structural constraints in clinical trial design. Under-recruitment directly leads to premature termination, while over-ambitious targets create severe operational drag.
The interactive histogram panel below reveals how planned participant cohorts are distributed across major research eras (1990–1999, 2000–2009, 2010–2019, and 2020–2026). Use the dropdown menu in the upper-left of the chart to inspect specific eras or compare all eras side-by-side, or hover over bars to view exact trial counts and percentages.
3. Trial Phase: The Phase II Vulnerability Spike
Phase of development is one of the strongest predictive signals for trial termination. As drugs transition from preliminary safety to formal proof-of-concept testing, the failure rate sharply peaks.
Use the interactive buttons above the chart to toggle between Termination Rate (%) and Study Volume Breakdown, or hover over bars to inspect exact counts and percentages.
4. Study Architecture: Randomization & Placebo Use
The design of a trial’s control mechanism directly impacts patient enrollment willingness, protocol compliance, and operational feasibility.
A. Randomization Status
Non-randomized interventional studies experience a significantly higher termination rate (8.4%) than randomized trials (5.5%), often reflecting single-arm exploratory designs that are vulnerable to early discontinuation.
B. Placebo Use
Placebo-controlled trials demand rigorous double-blinding, identical manufacturing of active and sham agents, and ethical consent for potential inactive treatment. Consequently, trials with reported placebo controls exhibit an 8.6% termination rate—more than 50% higher than trials without placebo controls (5.6%).
5. Protocol Scale: Interventions & Number of Conditions
A. Number of Interventions
As trials incorporate multiple drugs, combination therapies, or complex dosing arms, the termination hazard rises steadily. The data reveals a clear dose-response relationship between intervention count and study termination:
B. Number of Conditions Listed
Protocols targeting multiple comorbid conditions or broad diagnostic indications introduce diagnostic heterogeneity and patient subgroup stratification challenges:
6. Study Duration: The Attrition Timeline
How does elapsed study timeline correlate with termination? The chart below tracks termination rates across study duration brackets (from short studies under 6 months to multi-year longitudinal trials):
NoteThe 2–5 Year Vulnerability Window
Short studies (< 6 months) resolve quickly before major institutional or competitive shifts occur (3.4% failure). Studies extending into years 2 through 5 endure prolonged exposure to funding renewals, principal investigator relocations, and patient dropouts.
7. Protocol Complexity Score: Compounding Structural Risk
To capture the holistic operational burden of a clinical trial, we synthesized a Composite Study Complexity Score (0 to 5 points) incorporating: - Multi-arm design (\(\ge 3\) arms or \(\ge 3\) interventions) - Placebo control reporting - Blinded masking (double, triple, or quadruple) - Multi-site geographic footprint (\(\ge 6\) facilities) - Multi-endpoint burden (\(\ge 3\) primary outcomes)
Stratifying 602,514 studies by complexity score reveals a stark, linear escalation in failure risk: